Arizona Tribune - Reminder - Webcast/Conference Call to Discuss Fantastic PRIME Phase 1b Top-line Data

NYSE - LSE
CMSD 0% 21.18 $
CMSC -0.09% 21.29 $
JRI -0.4% 12.35 $
RIO -1.43% 103.3 $
RELX 0.66% 36.54 $
RYCEF -1.22% 20.5 $
GSK 1.08% 50.82 $
BCC -0.03% 78.75 $
RBGPF 0.11% 70.77 $
BTI -0.27% 56.13 $
BCE 0.26% 23.46 $
NGG -0.1% 79.35 $
AZN -1.12% 162.7 $
BP -0.45% 42.15 $
VOD 1% 16.04 $
Reminder - Webcast/Conference Call to Discuss Fantastic PRIME Phase 1b Top-line Data
Reminder - Webcast/Conference Call to Discuss Fantastic PRIME Phase 1b Top-line Data

Reminder - Webcast/Conference Call to Discuss Fantastic PRIME Phase 1b Top-line Data

SAN DIEGO, CA / ACCESS Newswire / September 9, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation, wants to remind you of our September 10th webcast at 8:30 am Eastern Time, which can be accessed here or to call in, please dial 888-506-0062 (toll free in the US), +1 973-528-0011 (if International) and use the participant access code 289672. We look forward to reviewing the data with you tomorrow morning.

Text size:

A copy of the original press release announcing data can be found here.
A copy of the presentation to be reviewed can be found here.

About Revelation Biosciences, Inc.

Revelation Biosciences, Inc. is a clinical stage life sciences company focused on rebalancing inflammation using its proprietary formulation Gemini. Revelation has multiple ongoing programs to evaluate Gemini, including as a prevention for post-surgical infection, as prevention for acute kidney injury and the treatment of chronic kidney disease.

For more information on Revelation, please visit https://www.revbiosciences.com.

Company Contact

Mike Porter
Investor Relations
Porter LaVay & Rose Inc.
Email: [email protected]

Chester Zygmont, III
Chief Financial Officer
Revelation Biosciences Inc.
Email: [email protected]

SOURCE: Revelation Biosciences, Inc.



View the original press release on ACCESS Newswire

G.P.Martin--AT